公开(公告)号：US09034883B2

公开(公告)日：2015-05-19

申请号：US13295174

申请日：2011-11-14

Applicant: Thomas Klein ,  Andreas Daiber ,  Odd-Eric Johansen ,  Michael Mark ,  Sanjaykumar Patel ,  Hans-Juergen Woerle

Inventor： Thomas Klein ,  Andreas Daiber ,  Odd-Eric Johansen ,  Michael Mark ,  Sanjaykumar Patel ,  Hans-Juergen Woerle

IPC: A61K31/52 ,  C07D473/12 ,  A61K31/519 ,  C07D473/06 ,  A61K31/397 ,  A61K31/522 ,  A61K31/5377 ,  A61K31/616 ,  A61K31/727 ,  A61K31/785 ,  A61K38/26 ,  A61K38/28 ,  A61K45/06

CPC classification number: A61K31/522 ,  A61K31/155 ,  A61K31/397 ,  A61K31/4184 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/616 ,  A61K31/727 ,  A61K31/785 ,  A61K38/26 ,  A61K38/28 ,  A61K45/06 ,  C07D473/06 ,  C07D473/12 ,  A61K2300/00

Abstract: The present invention relates to certain DPP-4 inhibitors for treating and/or preventing oxidative stress, vascular stress and/or endothelial dysfunction as well as to the use of such DPP-4 inhibitors in treatment and/or prevention of diabetic or non-diabetic patients, including patient groups at risk of cardiovascular and/or renal disease.

Abstract translation: 本发明涉及用于治疗和/或预防氧化应激，血管应激和/或内皮功能障碍的某些DPP-4抑制剂以及这种DPP-4抑制剂在治疗和/或预防糖尿病或非糖尿病中的用途 包括患有心血管和/或肾脏疾病风险的患者群体。

公开(公告)号：US20130303554A1

公开(公告)日：2013-11-14

申请号：US13892377

申请日：2013-05-13

Applicant: Thomas KLEIN ,  Andreas DAIBER ,  Klaus DUGI ,  Michael MARK ,  Thomas MUENZEL

Inventor： Thomas KLEIN ,  Andreas DAIBER ,  Klaus DUGI ,  Michael MARK ,  Thomas MUENZEL

IPC: C07D473/06 ,  A61K45/06 ,  A61K31/522

CPC classification number: C07D473/06 ,  A61K31/4985 ,  A61K31/5025 ,  A61K31/519 ,  A61K31/522 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention relates to methods for treating and/or preventing SIRS and/or sepsis comprising the administration of an effective amount of a certain DPP-4 inhibitor, as well as to the use of a certain DPP-4 inhibitor for treating and/or preventing a metabolic disease in a patient with or at risk of SIRS and/or sepsis.

Abstract translation: 本发明涉及用于治疗和/或预防SIRS和/或败血症的方法，其包括施用有效量的某些DPP-4抑制剂，以及使用某种DPP-4抑制剂治疗和/或 预防患有或具有SIRS和/或败血症风险的患者的代谢疾病。

公开(公告)号：US20140303097A1

公开(公告)日：2014-10-09

申请号：US14244196

申请日：2014-04-03

Applicant: Uli Christian BROEDL ,  Odd-Erik JOHANSEN ,  Gabriel Woojai KIM ,  Eric Williams MAYOUX ,  Afshin SALSALI ,  Nima SOLEYMANLOU ,  Maximilian von EYNATTEN ,  Hans-Juergen WOERLE ,  David Z.I. CHERNEY ,  Bruce A. PERKINS ,  Andreas DAIBER ,  Thomas MUENZEL

Inventor： Uli Christian BROEDL ,  Odd-Erik JOHANSEN ,  Gabriel Woojai KIM ,  Eric Williams MAYOUX ,  Afshin SALSALI ,  Nima SOLEYMANLOU ,  Maximilian von EYNATTEN ,  Hans-Juergen WOERLE ,  David Z.I. CHERNEY ,  Bruce A. PERKINS ,  Andreas DAIBER ,  Thomas MUENZEL

IPC: A61K31/7048 ,  A61K31/522 ,  A61K31/155

CPC classification number: A61K31/7048 ,  A61K9/2018 ,  A61K9/2866 ,  A61K31/155 ,  A61K31/522 ,  A61K31/7034 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.

Abstract translation: 本发明涉及用于治疗和/或预防氧化应激的某些SGLT-2抑制剂，例如在1型或2型糖尿病患者中，以及使用这样的SGLT-2抑制剂治疗和/或预防 患者心血管疾病，例如1型或2型糖尿病患者。 本发明还涉及用于治疗和/或预防代谢紊乱并预防，降低患者，例如1型或2型糖尿病患者心血管事件发生或延缓发生的风险的某些SGLT-2抑制剂。

公开(公告)号：US20120121530A1

公开(公告)日：2012-05-17

申请号：US13295174

申请日：2011-11-14

Applicant: Thomas KLEIN ,  Andreas DAIBER ,  Odd-Eric JOHANSEN ,  Michael MARK ,  Sanjaykumar PATEL ,  Hans-Juergen WOERLE

Inventor： Thomas KLEIN ,  Andreas DAIBER ,  Odd-Eric JOHANSEN ,  Michael MARK ,  Sanjaykumar PATEL ,  Hans-Juergen WOERLE

IPC: A61K31/522 ,  A61K38/26 ,  A61K31/397 ,  A61K31/616 ,  A61K31/727 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/785 ,  A61P9/00 ,  A61P39/06 ,  A61P3/10 ,  A61P3/08 ,  A61P3/04 ,  A61P3/06 ,  A61P9/12 ,  A61P9/10 ,  A61P19/10 ,  A61P29/00 ,  A61P1/16 ,  A61P27/02 ,  A61P25/00 ,  A61P13/12 ,  A61P15/00 ,  A61P3/00 ,  A61P27/12 ,  A61P25/28 ,  A61P9/04 ,  A61P9/06 ,  A61P1/18 ,  A61K38/28

CPC classification number: A61K31/522 ,  A61K31/155 ,  A61K31/397 ,  A61K31/4184 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/616 ,  A61K31/727 ,  A61K31/785 ,  A61K38/26 ,  A61K38/28 ,  A61K45/06 ,  C07D473/06 ,  C07D473/12 ,  A61K2300/00

Abstract: The present invention relates to certain DPP-4 inhibitors for treating and/or preventing oxidative stress, vascular stress and/or endothelial dysfunction as well as to the use of such DPP-4 inhibitors in treatment and/or prevention of diabetic or non-diabetic patients, including patient groups at risk of cardiovascular and/or renal disease.

Abstract translation: 本发明涉及用于治疗和/或预防氧化应激，血管应激和/或内皮功能障碍的某些DPP-4抑制剂以及这种DPP-4抑制剂在治疗和/或预防糖尿病或非糖尿病中的用途 包括患有心血管和/或肾脏疾病风险的患者群体。